109 related articles for article (PubMed ID: 7738615)
1. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
van Besien KW; Khouri IF; Giralt SA; McCarthy P; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Bellare N; Nath R
J Clin Oncol; 1995 May; 13(5):1096-102. PubMed ID: 7738615
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
3. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
4. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Toze CL; Shepherd JD; Connors JM; Voss NJ; Gascoyne RD; Hogge DE; Klingemann HG; Nantel SH; Nevill TJ; Phillips GL; Reece DE; Sutherland HJ; Barnett MJ
Bone Marrow Transplant; 2000 Mar; 25(6):605-12. PubMed ID: 10734294
[TBL] [Abstract][Full Text] [Related]
9. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
[TBL] [Abstract][Full Text] [Related]
12. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
16. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
18. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
19. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
